Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) improve survival outcomes in metastatic melanoma and non-small cell lung cancer (NSCLC). Preclinical evidence suggests that overexpression of cyclo-oxygenase-2 (COX2) in tumors facilitates immune evasion through prostaglandin E2 production and that COX...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shang-Jui, Khullar, Karishma, Kim, Sinae, Yegya-Raman, Nikhil, Malhotra, Jyoti, Groisberg, Roman, Crayton, Samuel H, Silk, Ann W, Nosher, John L, Gentile, Michael A, Mehnert, Janice M, Jabbour, Salma K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537331/
https://www.ncbi.nlm.nih.gov/pubmed/33020239
http://dx.doi.org/10.1136/jitc-2020-000889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537331/
https://www.ncbi.nlm.nih.gov/pubmed/33020239
http://dx.doi.org/10.1136/jitc-2020-000889

Ejemplares similares